Cargando…
Drug repurposing of dermatologic medications to treat coronavirus disease 2019: Science or fiction?
No pharmaceutical products have been demonstrated to be safe and effective to specifically treat coronavirus disease 2019 (COVID-19); therefore, the therapy administered to infected patients remains symptomatic and empiric. Alongside the development of new, often high-cost drugs, a different tactic...
Autores principales: | Vassileva, Snejina, Mateeva, Valeria, Drenovska, Kossara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959882/ https://www.ncbi.nlm.nih.gov/pubmed/34518001 http://dx.doi.org/10.1016/j.clindermatol.2021.01.020 |
Ejemplares similares
-
Case Report: Rowell Syndrome–Like Flare of Cutaneous Lupus Erythematosus Following COVID-19 Infection
por: Drenovska, Kossara, et al.
Publicado: (2022) -
Impact of COVID-19 on autoimmune blistering diseases
por: Drenovska, Kossara, et al.
Publicado: (2021) -
Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy
por: Drenovska, Kossara, et al.
Publicado: (2023) -
Commentary: COVID-19 pandemic — 1 Year later
por: Drenovska, Kossara, et al.
Publicado: (2021) -
Autoimmune connective tissue diseases in the COVID-19 pandemic
por: Dourmishev, Lyubomir, et al.
Publicado: (2021)